EA200801850A1 - Способ солюбилизации, диспергирования и стабилизации веществ, продукты, полученные этим способом, и их применение - Google Patents
Способ солюбилизации, диспергирования и стабилизации веществ, продукты, полученные этим способом, и их применениеInfo
- Publication number
- EA200801850A1 EA200801850A1 EA200801850A EA200801850A EA200801850A1 EA 200801850 A1 EA200801850 A1 EA 200801850A1 EA 200801850 A EA200801850 A EA 200801850A EA 200801850 A EA200801850 A EA 200801850A EA 200801850 A1 EA200801850 A1 EA 200801850A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- melt
- dispersed
- resin
- poloxamer
- substances
- Prior art date
Links
- 239000000126 substance Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000006185 dispersion Substances 0.000 title 1
- 230000007928 solubilization Effects 0.000 title 1
- 238000005063 solubilization Methods 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 239000000155 melt Substances 0.000 abstract 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 3
- 229940088623 biologically active substance Drugs 0.000 abstract 3
- 229960000502 poloxamer Drugs 0.000 abstract 3
- 229920001983 poloxamer Polymers 0.000 abstract 3
- 239000011347 resin Substances 0.000 abstract 3
- 229920005989 resin Polymers 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 239000013078 crystal Substances 0.000 abstract 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- 239000003925 fat Substances 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 229960001295 tocopherol Drugs 0.000 abstract 2
- 229930003799 tocopherol Natural products 0.000 abstract 2
- 235000010384 tocopherol Nutrition 0.000 abstract 2
- 239000011732 tocopherol Substances 0.000 abstract 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000004140 cleaning Methods 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000005461 lubrication Methods 0.000 abstract 1
- 230000008635 plant growth Effects 0.000 abstract 1
- 239000002689 soil Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/90—Block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Animal Husbandry (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hematology (AREA)
Abstract
Способ, заключающийся в том, что полоксамер, смолу и/или токоферол расплавляют и в этом расплаве диспергируют обрабатываемое вещество. После внесения обрабатываемого вещества в расплав его покрывают водой для предотвращения отверждения и самопроизвольно образующийся гель гомогенизируют. Образуется продукт, состоящий из прозрачного геля на основе минимум одного полоксамера, одной смолы или одного токоферола и одного в нём солюбилизированного, диспергированного и стабилизированного биологически активного вещества в консистенции от твердой и полутвердой, т.е. желеобразной, до жидкой. Мицеллы этого солюбилизата остаются стабильными даже ниже критической концентрации образования мицелл полоксамера при разбавлении. Использование этого продукта зависит от солюбилизируемого биологически активного вещества и возможно в растворении жиров, белков, смол и смолоподобных веществ всех видов, а также - в удалении с поверхностей жиров, белков и смолоподобных веществ всех видов, для очистки и для смазки. Когда в таком расплаве диспергируют биологически активное вещество для роста растений, то проводится охлаждение в расплаве, а не покрытие водой. Расплав в хрупком состоянии затем может быть грубо измельчен в ножевой мельнице и после этого во влажном состоянии перемолот в молотковой дробилке или эмульсионной мельнице до уменьшения диаметра кристаллов расплава ниже 5 мкм. Затем кристаллы расплава растворяют или диспергируют в воде, получая раствор, который можно вносить в грунт для усвоения растением через корневую систему или непосредственно опрыскать надземную часть растения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH3772006 | 2006-03-10 | ||
PCT/CH2007/000131 WO2007104173A2 (de) | 2006-03-10 | 2007-03-09 | Verfahren zum solubilisieren, dispergieren und stabilisieren von stoffen, nach dem verfahren hergestellte erzeugnisse sowie die verwendung derselben |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200801850A1 true EA200801850A1 (ru) | 2009-06-30 |
EA026670B1 EA026670B1 (ru) | 2017-05-31 |
Family
ID=38137765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200801850A EA026670B1 (ru) | 2006-03-10 | 2007-03-09 | Способ солюбилизации, диспергирования и стабилизации веществ, продукты, полученные этим способом, и их применение |
Country Status (17)
Country | Link |
---|---|
US (2) | US8703195B2 (ru) |
EP (1) | EP1993515B1 (ru) |
JP (2) | JP5678359B2 (ru) |
KR (1) | KR101433962B1 (ru) |
CN (1) | CN101400337A (ru) |
AT (1) | ATE437627T1 (ru) |
AU (1) | AU2007224940B2 (ru) |
BR (1) | BRPI0708773B1 (ru) |
CA (1) | CA2643389C (ru) |
DE (1) | DE502007001190D1 (ru) |
DK (1) | DK1993515T3 (ru) |
EA (1) | EA026670B1 (ru) |
ES (1) | ES2330898T3 (ru) |
HR (1) | HRP20090573T1 (ru) |
PL (1) | PL1993515T3 (ru) |
PT (1) | PT1993515E (ru) |
WO (1) | WO2007104173A2 (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5385282B2 (ja) | 2007-09-11 | 2014-01-08 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | 治療剤としての血小板フィブリノーゲン受容体ヘキサペプチドアンタゴニストおよびα−エンドルフィンの使用 |
WO2009033797A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a petide as a therapeutic agent |
KR20100061676A (ko) | 2007-09-11 | 2010-06-08 | 몬도바이오테크 래보래토리즈 아게 | 녹농균 감염 치료에서 치료제로서의 멜라닌세포-자극 호르몬 방출-저해 인자의 용도 |
AU2008306132A1 (en) | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Use of GRF-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
RU2010114003A (ru) | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение пептида фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae |
CA2699169A1 (en) | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Therapeutic uses of intermedin 47 and 53 peptides |
JP2010539042A (ja) | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | ペプチドの治療剤としての使用 |
US20100204152A1 (en) | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of gluten exorphin c : as a therapeutic agent |
EP2187938A2 (en) | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-arg as a therapeutic agent |
CA2699168A1 (en) | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
EP2197462A2 (en) | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
WO2009040068A2 (en) | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
WO2009040006A1 (en) | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Spantide for therapeutic uses |
US20100210533A1 (en) | 2007-09-11 | 2010-08-19 | Dorian Bevec | Use of urocortin and corticotropin-releasing factor as therapeutic agents |
KR20120060945A (ko) | 2009-05-11 | 2012-06-12 | 버그 바이오시스템즈, 엘엘씨 | 환경대사적 전환인자, 다차원 세포내 분자 또는 환경적 영향인자를 사용한 대사적 장애의 치료 방법 |
EP2359702B1 (en) | 2010-01-22 | 2014-06-04 | Symrise AG | Solubilization agent for solubilizing polyphenols, flavonoids and/or diterpenoid glucosides |
MY163995A (en) * | 2010-03-12 | 2017-11-15 | Berg Llc | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
SI2390284T1 (sl) | 2010-05-28 | 2012-07-31 | Omya Development Ag | Postopek za izdelavo suspenzij mineralnih materialov z visoko vsebnostjo trdnih snovi |
JP6092844B2 (ja) | 2011-04-04 | 2017-03-08 | バーグ エルエルシー | 中枢神経系腫瘍の治療方法 |
MX369543B (es) | 2011-06-17 | 2019-11-12 | Berg Llc | Composiciones farmaceuticas inhalables. |
JP5869856B2 (ja) * | 2011-11-30 | 2016-02-24 | キユーピー株式会社 | 容器入り大根おろし含有液状調味料 |
BRPI1106762A2 (pt) * | 2011-12-22 | 2013-11-05 | Bioactive Biomateriais Ltda | Composição polimérica contendo bioativos naturais aplicáveis em formulações farmacêuticas e cosméticas |
KR101451401B1 (ko) * | 2012-12-14 | 2014-10-22 | 주식회사 휴메딕스 | 비타민 c와 비타민 e의 컨쥬게이트 및 그를 포함하는 항산화제 |
JP6122646B2 (ja) * | 2013-01-23 | 2017-04-26 | 昭和電工株式会社 | 皮膚外用剤 |
EA032775B1 (ru) | 2013-04-08 | 2019-07-31 | Берг Ллк | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 |
BR112015027112A2 (pt) * | 2013-05-06 | 2017-07-25 | Basf Se | uso de uma mistura, e, formulação de ingrediente ativo aquoso |
JP6232807B2 (ja) * | 2013-07-30 | 2017-11-22 | ユーハ味覚糖株式会社 | グミキャンディ |
EP3730131A1 (en) | 2013-09-04 | 2020-10-28 | Berg LLC | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
EP3216443A1 (en) | 2016-03-10 | 2017-09-13 | Athenion AG | Beverage preparation capsule for delivery of a solubilisate |
EP3388054A1 (en) | 2017-04-12 | 2018-10-17 | Athenion AG | Dispensing cap containing a solubilisate of a pharmaceutically active agent or dietary supplement |
EP3424494A1 (en) * | 2017-07-07 | 2019-01-09 | SolMic Research GmbH | Stable cannabinoid compositions |
CN108271814A (zh) * | 2018-01-21 | 2018-07-13 | 王小凤 | 一种糖尿病患者可食用的苹果的培育剂及其制备方法 |
CN108210360B (zh) * | 2018-02-06 | 2021-02-12 | 德之馨(上海)有限公司 | 一种水溶性美白配方及其制备方法和用途 |
EP3869961B1 (en) * | 2018-10-24 | 2022-12-07 | Syngenta Participations Ag | New abamectin soluble concentrate composition (sl) |
WO2020250242A1 (en) * | 2019-06-10 | 2020-12-17 | Godrej Agrovet Limited | Bud break formulation |
JP7504589B2 (ja) * | 2019-12-27 | 2024-06-24 | ポーラ化成工業株式会社 | 透明な可溶化組成物 |
EP3909564A1 (de) | 2020-05-12 | 2021-11-17 | Metabolic Tuning AG | Feste lösung aus gummi arabicum und wenigstens einem fettlöslichen wirkstoff |
KR102365402B1 (ko) * | 2021-05-31 | 2022-02-18 | 김상태 | 사포닌을 함유한 깻잎 및 이의 생산방법 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2953496A (en) * | 1958-12-02 | 1960-09-20 | Upjohn Co | Vitamin emulsion |
CA1088427A (en) * | 1975-12-22 | 1980-10-28 | Andrew W. Finkstein | Imidazoline-containing hair shampoo compositions |
JPS5660565A (en) * | 1979-10-22 | 1981-05-25 | Dainichiseika Color Chem | Composition for deodorizing aromatic |
US4383987A (en) * | 1981-06-26 | 1983-05-17 | Colgate/Palmolive Company | Foaming dentifrice containing nonionic surface active agent |
GB2181737A (en) * | 1985-08-29 | 1987-04-29 | Avent Medical Ltd | Liquid shampoo composition |
US4810503A (en) * | 1987-03-31 | 1989-03-07 | Basf Corporation | Polymers which form gels at low concentrations in water |
PH31381A (en) * | 1994-02-07 | 1998-10-29 | Isk Biotech Corp | Pesticidal micronutrient compositions containing zinc oxide. |
US5861174A (en) * | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6193954B1 (en) * | 1997-03-21 | 2001-02-27 | Abbott Laboratories | Formulations for pulmonary delivery of dopamine agonists |
US6027716A (en) * | 1997-04-02 | 2000-02-22 | Farmo-Nat Ltd. | Synergistic herbal extracts |
US6228347B1 (en) * | 1997-12-01 | 2001-05-08 | Thione International, Inc. | Antioxidant gel for gingival conditions |
US6197305B1 (en) * | 1998-01-05 | 2001-03-06 | Farmo-Nat Ltd. | Anti-fungal compositions with prolonged activity |
US6200550B1 (en) * | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
AUPP915099A0 (en) * | 1999-03-12 | 1999-04-15 | Monk, Michael Mendel | Improved composition for oral administration |
KR20070058028A (ko) * | 1999-05-24 | 2007-06-07 | 소너스파머슈티칼즈인코포레이티드 | 난용성 약물용 에멀젼 부형제 |
DE60033671T2 (de) * | 1999-09-11 | 2007-12-06 | The Procter & Gamble Company, Cincinnati | Polyoxyalkylen-blockcopolymere enthaltende giessfähige flüssige träger |
BE1013366A6 (nl) * | 2000-03-29 | 2001-12-04 | Panin Giorgio | Een detergent samenstelling voor persoonlijke hygiene met een hoge inhoud aan vitamine e of derivaten daarvan. |
DE10343872A1 (de) * | 2003-09-23 | 2005-04-21 | Bayer Cropscience Ag | Suspensionskonzentrate |
US7713440B2 (en) * | 2003-10-08 | 2010-05-11 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
WO2005053652A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
WO2006024138A1 (en) * | 2004-08-30 | 2006-03-09 | Taro Pharmaceutical Industries Ltd. | A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol |
-
2007
- 2007-03-09 US US12/281,834 patent/US8703195B2/en not_active Expired - Fee Related
- 2007-03-09 WO PCT/CH2007/000131 patent/WO2007104173A2/de active Application Filing
- 2007-03-09 JP JP2008557575A patent/JP5678359B2/ja not_active Expired - Fee Related
- 2007-03-09 EA EA200801850A patent/EA026670B1/ru not_active IP Right Cessation
- 2007-03-09 CA CA2643389A patent/CA2643389C/en active Active
- 2007-03-09 CN CNA2007800086123A patent/CN101400337A/zh active Pending
- 2007-03-09 AU AU2007224940A patent/AU2007224940B2/en not_active Ceased
- 2007-03-09 DE DE200750001190 patent/DE502007001190D1/de active Active
- 2007-03-09 DK DK07710794T patent/DK1993515T3/da active
- 2007-03-09 AT AT07710794T patent/ATE437627T1/de active
- 2007-03-09 EP EP07710794A patent/EP1993515B1/de active Active
- 2007-03-09 PT PT07710794T patent/PT1993515E/pt unknown
- 2007-03-09 PL PL07710794T patent/PL1993515T3/pl unknown
- 2007-03-09 ES ES07710794T patent/ES2330898T3/es active Active
- 2007-03-09 BR BRPI0708773-0A patent/BRPI0708773B1/pt not_active IP Right Cessation
- 2007-03-09 KR KR1020087023964A patent/KR101433962B1/ko active IP Right Grant
-
2009
- 2009-10-28 HR HR20090573T patent/HRP20090573T1/hr unknown
-
2014
- 2014-02-19 US US14/184,145 patent/US9114167B2/en not_active Expired - Fee Related
- 2014-08-15 JP JP2014165434A patent/JP2015028028A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20140193513A1 (en) | 2014-07-10 |
ATE437627T1 (de) | 2009-08-15 |
KR20080108262A (ko) | 2008-12-12 |
US20090280987A1 (en) | 2009-11-12 |
CA2643389A1 (en) | 2007-09-20 |
DK1993515T3 (da) | 2009-12-07 |
US9114167B2 (en) | 2015-08-25 |
EP1993515A2 (de) | 2008-11-26 |
WO2007104173A3 (de) | 2007-11-22 |
AU2007224940A1 (en) | 2007-09-20 |
WO2007104173B1 (de) | 2008-01-10 |
WO2007104173A2 (de) | 2007-09-20 |
DE502007001190D1 (de) | 2009-09-10 |
EP1993515B1 (de) | 2009-07-29 |
AU2007224940B2 (en) | 2013-08-29 |
CN101400337A (zh) | 2009-04-01 |
PL1993515T3 (pl) | 2010-01-29 |
EA026670B1 (ru) | 2017-05-31 |
JP5678359B2 (ja) | 2015-03-04 |
JP2015028028A (ja) | 2015-02-12 |
US8703195B2 (en) | 2014-04-22 |
BRPI0708773B1 (pt) | 2021-10-19 |
PT1993515E (pt) | 2009-11-05 |
HRP20090573T1 (hr) | 2009-11-30 |
ES2330898T3 (es) | 2009-12-16 |
BRPI0708773A2 (pt) | 2011-06-14 |
KR101433962B1 (ko) | 2014-08-25 |
JP2009531305A (ja) | 2009-09-03 |
CA2643389C (en) | 2014-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200801850A1 (ru) | Способ солюбилизации, диспергирования и стабилизации веществ, продукты, полученные этим способом, и их применение | |
Goindi et al. | An ionic liquid-in-water microemulsion as a potential carrier for topical delivery of poorly water soluble drug: Development, ex-vivo and in-vivo evaluation | |
CN1655769B (zh) | 多糖胶囊及其制备方法 | |
Tan et al. | Effect extraction temperature on the emulsifying properties of gelatin from black tilapia (Oreochromis mossambicus) skin | |
Kalaitzaki et al. | Biocompatible colloidal dispersions as potential formulations of natural pyrethrins: a structural and efficacy study | |
ATE200616T1 (de) | Hydrophobe polymer mikropartikel | |
EA200501285A1 (ru) | Способ получения липосомальных препаратов | |
CN102578110A (zh) | 青蒿素缓释体的制备方法 | |
GB2334213A (en) | Agricultural pesticide formulations | |
CN104027294B (zh) | 含岩藻多糖和石榴提取物的眼霜及其制备方法 | |
CN105284818A (zh) | 一种含氯化胆碱的组合物 | |
CN104706575A (zh) | 一种氟比洛芬酯脂肪乳浓缩液、其制备方法及用途 | |
CN102258012A (zh) | 一种氰氟草酯水乳剂及其制备方法 | |
EP3468531A1 (fr) | Compositions lipidiques auto-emulsionnables | |
CN106614598A (zh) | 一种杀虫剂及其应用 | |
CN107333759A (zh) | 光控缓释农药制剂及其制备方法 | |
CN101911949A (zh) | 含咪鲜胺和左旋α-松油醇的杀菌剂组合物及其生产方法 | |
FR2798818A1 (fr) | Additifs de type (co) polymeres floculants et procedes pour reduire la tare des plantes a tubercules lors de la recolte | |
CN104666245A (zh) | 一种缓释性松油烯-4-醇微乳及其制备方法 | |
CN101946794A (zh) | 一种氯氰菊酯水乳剂及其制备方法 | |
CN104706584A (zh) | 一种伊维菌素脂肪乳浓缩液、其制备方法及用途 | |
KR101898243B1 (ko) | 고 함량 오일을 함유하는 무-계면활성제의 수중유형 화장료 조성물 | |
CN110051687A (zh) | 一种防滴型聚维酮碘消毒浸剂及其制备方法和应用 | |
AU779666B2 (en) | Aqueous suspension pesticide preparation | |
CN101073322A (zh) | 米尔贝霉素和米尔贝肟微乳剂、水乳剂、悬浮剂制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |